Background
- There is minimal prospective data on outcomes with immune checkpoint inhibitors for patients with predominant histologic subtype urothelial carcinoma (hsUC) 1,2
- 2IR score compares expression of genes involved in anti-tumorigenic adaptive immune response and pro-tumorigenic inflammation 3
- We previously validated the 2IR score in a UC real world cohort – high 2IR associated with favorable survival and correlated with known markers of immune response
- Objective is to compare 2IR score in hsUC (variant predominant) to pure UC (pUC) to predict response to immunotherapy